NASDAQ:ICPT
Delisted
Intercept Pharmaceuticals Stock News
$19.00
+0 (+0%)
At Close: Feb 06, 2024
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
02:26pm, Monday, 13'th Mar 2023 Zacks Investment Research
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
11:29am, Monday, 13'th Mar 2023
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
05:01pm, Friday, 10'th Mar 2023 Zacks Investment Research
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
02:05pm, Friday, 10'th Mar 2023 GlobeNewswire Inc.
Advisory Committee Meeting scheduled for May 19, 2023
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
01:47pm, Friday, 10'th Mar 2023
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
12:29pm, Friday, 10'th Mar 2023
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Fac
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
11:49am, Friday, 10'th Mar 2023
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Fac
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
08:00am, Thursday, 09'th Mar 2023
MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
04:08pm, Friday, 03'rd Mar 2023 Zacks Investment Research
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
12:48pm, Friday, 03'rd Mar 2023
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates
01:55pm, Thursday, 02'nd Mar 2023 Zacks Investment Research
Intercept (ICPT) delivered earnings and revenue surprises of 20.75% and 0.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals, Inc. (ICPT) Q4 2022 Earnings Call Transcript
12:56pm, Thursday, 02'nd Mar 2023
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q4 2022 Results Conference Call March 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - Pres
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates
10:32am, Thursday, 02'nd Mar 2023
Intercept (ICPT) delivered earnings and revenue surprises of 20.75% and 0.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates
12:25am, Wednesday, 01'st Mar 2023 Zacks Investment Research
Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
06:47pm, Monday, 27'th Feb 2023 Zacks Investment Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
